5DXU

p110delta/p85alpha with GDC-0326

5DXU の概要

• エントリーDOI: 10.2210/pdb5dxu/pdb
• 関連するPDBエントリー: 5DXH 5DXT
• 分子名称: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, Phosphatidylinositol 3-kinase regulatory subunit alpha, (2S)-2-({2-[1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}oxy)propanamide, ... (4 entities in total)
• 機能のキーワード: lipid kinase, inhibitor, transferase-inhibitor complex, transferase/inhibitor
• 由来する生物種: Homo sapiens (Human); 詳細
• 細胞内の位置: Cytoplasm : O00329
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 140763.79

構造登録者

Heffron, T.P.,Heald, R.A.,Ndubaku, C.,Wei, B.Q.,Augustin, M.,Do, S.,Edgar, K.,Eigenbrot, C.,Friedman, L.,Gancia, E.,Jackson, P.S.,Jones, G.,Kolesnikov, A.,Lee, L.B.,Lesnick, J.D.,Lewis, C.,McLean, N.,Mortle, M.,Nonomiya, J.,Pang, J.,Price, S.,Prior, W.W.,Salphati, L.,Sideris, S.,Staben, S.T.,Steinbacher, S.,Tsui, V.,Wallin, J.,Sampath, D.,Olivero, A. (登録日: 2015-09-23, 公開日: 2016-01-27, 最終更新日: 2024-03-06)

主引用文献

Heffron, T.P.,Heald, R.A.,Ndubaku, C.,Wei, B.,Augistin, M.,Do, S.,Edgar, K.,Eigenbrot, C.,Friedman, L.,Gancia, E.,Jackson, P.S.,Jones, G.,Kolesnikov, A.,Lee, L.B.,Lesnick, J.D.,Lewis, C.,McLean, N.,Mortl, M.,Nonomiya, J.,Pang, J.,Price, S.,Prior, W.W.,Salphati, L.,Sideris, S.,Staben, S.T.,Steinbacher, S.,Tsui, V.,Wallin, J.,Sampath, D.,Olivero, A.G.
The Rational Design of Selective Benzoxazepin Inhibitors of the alpha-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
J.Med.Chem., 59:985-1002, 2016

PubMed Abstract: Inhibitors of the class I phosphoinositide 3-kinase (PI3K) isoform PI3Kα have received substantial attention for their potential use in cancer therapy. Despite the particular attraction of targeting PI3Kα, achieving selectivity for the inhibition of this isoform has proved challenging. Herein we report the discovery of inhibitors of PI3Kα that have selectivity over the other class I isoforms and all other kinases tested. In GDC-0032 (3, taselisib), we previously minimized inhibition of PI3Kβ relative to the other class I insoforms. Subsequently, we extended our efforts to identify PI3Kα-specific inhibitors using PI3Kα crystal structures to inform the design of benzoxazepin inhibitors with selectivity for PI3Kα through interactions with a nonconserved residue. Several molecules selective for PI3Kα relative to the other class I isoforms, as well as other kinases, were identified. Optimization of properties related to drug metabolism then culminated in the identification of the clinical candidate GDC-0326 (4).

PubMed: 26741947
DOI: 10.1021/acs.jmedchem.5b01483

実験手法

X-RAY DIFFRACTION (2.64 Å)